This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
ImmunityBio vs. Moderna: Which Biotech Has More Upside Potential?
by Sundeep Ganoria
IBRX and MRNA hinge on single-drug success, but pipeline depth, growth plans and risks set them apart in the race for biotech upside.
MRKPositive Net Change MRNANegative Net Change IBRXPositive Net Change
biotechs medical medical-devices messenger-rna pharmaceuticals vaccines
Reasons to Add Cooper Companies Stock to Your Portfolio Now
by Zacks Equity Research
COO rides on premium lens momentum and margin gains, but Asia weakness and geopolitical risks test near-term growth outlook.
ISRGNegative Net Change ALGNNegative Net Change CAHNegative Net Change COONegative Net Change
medical medical-devices
PLSE Accelerates Cardiac Catheter Program After Breakthrough AFib Data
by Zacks Equity Research
Pulse Biosciences pivots to its nPulse AFib system after strong clinical results, ramping investment to accelerate development and future commercialization.
ISRGNegative Net Change CAHNegative Net Change PAHCNegative Net Change PLSENegative Net Change
medical medical-devices
Here's Why You Should Retain Integer Holdings Stock in Your Portfolio
by Zacks Equity Research
ITGR's strong product sales and R&D momentum support growth outlook, but near-term product adoption delays and margin pressure remain key risks.
ISRGNegative Net Change CAHNegative Net Change PAHCNegative Net Change ITGRNegative Net Change
medical medical-devices
PacBio Wins Basecamp Research Deal for Trillion Gene Atlas Initiative
by Zacks Equity Research
PACB wins Basecamp deal to power Trillion Gene Atlas using HiFi sequencing, advancing AI-driven drug discovery with high-accuracy genomic data.
ISRGNegative Net Change CAHNegative Net Change PACBNegative Net Change PAHCNegative Net Change
medical medical-devices
Is AUNA S.A. a Solid Investment Opportunity Post Q4 Earnings?
by Moumi Mondal
AUNA rallies after Q4 as Peru growth, Mexico recovery signals, and rising cash flow strengthen its outlook and balance sheet.
AHCONegative Net Change AVAHNegative Net Change AUNANegative Net Change
medical medical-devices
HIMS vs. DOCS: Which Digital Health Stock Offers Better Upside Now?
by Debanjana Dey
Hims & Hers and Doximity are taking different paths in digital health, but which stock offers stronger upside now? Let's dive in.
HIMSNegative Net Change DOCSNegative Net Change
medical medical-devices
LivaNova Expands OSA Care With FDA-Approved aura6000 System
by Zacks Equity Research
LIVN wins FDA nod for its aura6000 sleep apnea system, marking a pivotal step in neurostimulation with strong trial results and new growth potential.
ISRGNegative Net Change CAHNegative Net Change PAHCNegative Net Change LIVNNegative Net Change
medical medical-devices
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
by Zacks Equity Research
FMS eyes growth on value-based care surge and FME25+ savings, but regulatory headwinds, flat volumes and China weakness cloud outlook.
ISRGNegative Net Change CAHNegative Net Change FMSNegative Net Change PAHCNegative Net Change
medical medical-devices
BTSG Growth Drivers in 2026 Across Specialty and Providers
by Indrajit Bandyopadhyay
BTSG leans on specialty and provider growth in 2026, with margin expansion expected to outpace revenue despite near-term pharmacy headwinds.
CVSNegative Net Change OPCHNegative Net Change BTSGNegative Net Change
medical medical-devices